Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 1;13(2):450-464.
doi: 10.7150/jca.68264. eCollection 2022.

The new insight of treatment in Cholangiocarcinoma

Yuhang Li  1 , Yinghui Song  1   2 , Sulai Liu  1   2   3
Affiliations
Review

The new insight of treatment in Cholangiocarcinoma

Yuhang Li et al. J Cancer. .

Abstract

Cholangiocarcinoma (CCA) is a relatively rare malignant tumor originating from the bile duct epithelial cells, and it is one of the malignant tumors with fast growth in incidence and death rate in recent years. CCA carries a very poor prognosis due to a typically late clinical presentation and a poor response to current therapeutics. Currently, surgery is the only possible curative treatment, radiotherapy and chemotherapy also play an important role in slowing down disease progression, while targeted therapy and immunotherapy are changing with each passing day and their combined effect may have great potential for the treatment of CCA; Clinical trials of various treatment options for CCA are also being conducted. This article reviews the different treatment options for CCA and explores the adjuvant treatment for it from a new perspective. In the future, the goal of treatment should be multiple and combined for different CCA patients to achieve individualized programs and improve overall survival.

Keywords: Cholangiocarcinoma; Insight; Treatment.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Different treatment of intrahepatic and extrahepatic cholangiocarcinoma.
Figure 2
Figure 2
Treatments for cholangiocarcinoma.
Figure 3
Figure 3
Treatment planning process for cholangiocarcinoma.
See this image and copyright information in PMC

References

    1. Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019. 39 Suppl 1. - PubMed
    1. Krasinskas AM. Cholangiocarcinoma. Surg Pathol Clin. 2018;11:403–29. - PubMed
    1. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215–29. - PMC - PubMed
    1. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67:93–9. - PubMed
    1. Razumilava N, Gores GJ. Combination of gemcitabine and cisplatin for biliary tract cancer: a platform to build on. J Hepatol. 2011;54:577–8. - PubMed